文献速递类风湿关节炎其他结缔组织病

生物制剂改善类风湿关节炎相关进展性肺纤维化的疗效

Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究回顾性分析2484例启动bDMARDs的RA患者中135例RA相关PPF,评估bDMARDs疗效与安全性。52周时bDMARDs显著改善CDAI,肺功能和CT评分稳定;IL-6Ri较TNFi改善FVC,CTLA4-Ig不良事件较少。

要点

  • bDMARDs治疗52周可显著改善RA相关PPF患者的CDAI,肺功能和CT评分保持稳定
  • IL-6Ri较TNFi显著改善FVC,CTLA4-Ig不良事件发生率较低
  • IL-6Ri治疗、非UIP型及52周CDAI较低是FVC改善的独立预测因素

核心结论

  • bDMARDs紧密控制RA疾病活动对RA相关PPF至关重要
  • IL-6Ri可能有助于改善FVC,而CTLA4-Ig可能具有较好的安全性

研究设计与样本

  • 回顾性真实世界研究,纳入2484例启动bDMARDs的RA患者,其中443例RA相关ILD,135例RA相关PPF(TNFi n=35,CTLA4-Ig n=45,IL-6Ri n=55)
  • 主要结局为第52周肺功能与CT视觉评分变化,采用倾向性评分逆概率治疗加权(PS-IPTW)比较组间差异

主要发现

  • bDMARDs治疗52周显著改善CDAI,肺功能与CT评分保持稳定
  • PS-IPTW校正后,各组CDAI、CT评分及药物保留率无显著差异
  • IL-6Ri组FVC较TNFi组改善(-3.2% vs +3.3%,P=0.011;Cohen's d=0.630)
  • CTLA4-Ig组不良事件较少
  • 多因素logistic回归显示IL-6Ri治疗、非UIP型及52周CDAI较低是FVC改善的独立预测因素

关键数值与推荐

  • FVC变化:IL-6Ri组-3.2% vs TNFi组+3.3%,P=0.011,Cohen's d=0.630
  • PS-IPTW校正后各组CDAI、CT评分及药物保留率无显著差异
  • CTLA4-Ig组不良事件发生率较低

临床怎么用

  • 对RA相关PPF患者,使用bDMARDs紧密控制疾病活动可能有助于稳定肺功能
  • IL-6Ri可能优先用于改善FVC,CTLA4-Ig可能优先用于安全性考虑
  • 非UIP型及较低CDAI与FVC改善相关,可作为疗效监测参考

局限性

  • 回顾性真实世界研究,样本量有限(135例PPF),可能存在选择偏倚
  • 未报告影像学进展、急性加重及具体不良事件类型等细节

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA)-associated progressive pulmonary fibrosis (PPF). METHODS: Real-world data were retrospectively collected in RA-associated PPF during the first year after bDMARD initiation. The primary outcome was change in pulmonary function and computed tomography (CT) visual scores at week 52. The secondary outcomes included comparisons of pulmonary function, CT scores, Clinical Disease Activity Index (CDAI), drug retention rates and adverse event rates over 52 weeks among the tumour necrosis factor inhibitor (TNFi), cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin (CTLA4-Ig) and interleukin-6 receptor inhibitor (IL-6Ri), using propensity score-based inverse probability of treatment weighting (PS-IPTW). RESULTS: Among 2484 patients with RA initiating bDMARDs, 443 had RA-associated interstitial lung disease (ILD) and 135 had RA-associated PPF (TNFi, n = 35; CTLA4-Ig, n = 45; IL-6Ri, n = 55). Treatment with bDMARDs markedly improved CDAI at week 52, and pulmonary function and CT scores remained stable. PS-IPTW-adjusted comparisons showed no significant differences in CDAI, CT scores or drug retention rates among the bDMARD groups. However, forced vital capacity (FVC) improved in IL-6Ri compared with TNFi (-3.2% vs + 3.3%, P = 0.011; Cohen's d = 0.630). Adverse events were less frequent in CTLA4-Ig. Multivariate logistic regression analysis identified IL-6Ri treatment, non-usual interstitial pneumonia (UIP) pattern and lower CDAI at week 52 as independent predictors of FVC improvement. CONCLUSION: Tight control of RA disease activity with bDMARDs appears crucial in RA-associated PPF. In this real-world comparative study, IL-6Ri may have contributed to improved FVC, whereas CTLA4-Ig may have a favourable safety profile.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kanda R, Tanaka Y, Miyazaki Y, et al. Effectiveness of biological disease-modifying antirheumatic drugs in progressive pulmonary fibrosis associated with rheumatoid arthritis. Rheumatology (Oxford). 2026. PMID: 42623111. doi:10.1093/rheumatology/keag421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。